{"id":"NCT04431453","sponsor":"Gilead Sciences","briefTitle":"Study of Remdesivir in Participants Below 18 Years Old With COVID-19","officialTitle":"A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-21","primaryCompletion":"2023-02-10","completion":"2023-02-10","firstPosted":"2020-06-16","resultsPosted":"2023-12-22","lastUpdate":"2024-02-06"},"enrollment":59,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"Remdesivir","otherNames":["GS-5734™","Veklury®"]}],"arms":[{"label":"Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg","type":"EXPERIMENTAL"},{"label":"RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg","type":"EXPERIMENTAL"}],"summary":"The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)","effectByArm":[{"arm":"Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg","deltaMin":91.7,"sd":null},{"arm":"RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg","deltaMin":58.3,"sd":null},{"arm":"RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg","deltaMin":75,"sd":null},{"arm":"RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg","deltaMin":58.3,"sd":null},{"arm":"RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg","deltaMin":66.7,"sd":null},{"arm":"RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":32,"countries":["United States","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=GS-US-540-5823"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":12},"commonTop":["Constipation","Acute kidney injury","Hyperglycaemia","Hypertension","Anaemia"]}}